Redhill Biopharma Ltd
RDHL1.150USD
-0.035-2.95%
收盘 12/24, 13:00（美东）报价延迟15分钟
3.83M总市值
0.02市盈率 TTM
关于 Redhill Biopharma Ltd 公司
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Redhill Biopharma Ltd简介
公司代码RDHL
公司名称Redhill Biopharma Ltd
上市日期Feb 01, 2011
CEOBen-Asher (Dror)
员工数量35
证券类型Depository Receipt
年结日Feb 01
公司地址21 Ha'arba'a St.
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编6473921
电话97235413131
网址https://www.redhillbio.com/
公司代码RDHL
上市日期Feb 01, 2011
CEOBen-Asher (Dror)
Redhill Biopharma Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Gagnon Securities LLC
0.35%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
其他
99.55%
持股股东
持股股东
占比
Gagnon Securities LLC
0.35%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
其他
99.55%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
0.40%
Research Firm
0.08%
Investment Advisor
0.04%
其他
99.48%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
38
103.50K
3.11%
-21.59K
2025Q2
39
100.72K
4.39%
-24.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
2023Q2
113
26.79K
29.96%
+840.00
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Desjardins Securities Inc.
3.39K
0.1%
--
--
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
1.77K
0.05%
+380.00
+27.38%
Jun 30, 2025
BofA Global Research (US)
303.00
0.01%
--
--
Jun 30, 2025
GAMMA Investing LLC
135.00
0%
-1.93K
-93.45%
Sep 30, 2025
SBI Securities Co., Ltd.
2.00K
0.06%
+2.00K
+39980.00%
Jun 30, 2025
UBS Switzerland AG
1.00
0%
--
--
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
公告日期
类型
比率
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
常见问题
Redhill Biopharma Ltd的前五大股东是谁？
Redhill Biopharma Ltd 的前五大股东如下：
Desjardins Securities Inc.持有股份：3.39K，占总股份比例：0.10%。
Rhumbline Advisers Ltd. Partnership持有股份：1.77K，占总股份比例：0.05%。
BofA Global Research (US)持有股份：303.00，占总股份比例：0.01%。
GAMMA Investing LLC持有股份：135.00，占总股份比例：0.00%。
SBI Securities Co., Ltd.持有股份：2.00K，占总股份比例：0.06%。
Desjardins Securities Inc.持有股份：3.39K，占总股份比例：0.10%。
Rhumbline Advisers Ltd. Partnership持有股份：1.77K，占总股份比例：0.05%。
BofA Global Research (US)持有股份：303.00，占总股份比例：0.01%。
GAMMA Investing LLC持有股份：135.00，占总股份比例：0.00%。
SBI Securities Co., Ltd.持有股份：2.00K，占总股份比例：0.06%。
Redhill Biopharma Ltd的前三大股东类型是什么？
Redhill Biopharma Ltd 的前三大股东类型分别是：
Gagnon Securities LLC
Desjardins Securities Inc.
Rhumbline Advisers Ltd. Partnership
Gagnon Securities LLC
Desjardins Securities Inc.
Rhumbline Advisers Ltd. Partnership
有多少机构持有Redhill Biopharma Ltd(RDHL)的股份？
截至2025Q3，共有38家机构持有Redhill Biopharma Ltd的股份，合计持有的股份价值约为103.50K，占公司总股份的3.11%。与2025Q2相比，机构持股有所增加，增幅为-1.28%。
哪个业务部门对Redhill Biopharma Ltd的收入贡献最大？
在--，--业务部门对Redhill Biopharma Ltd的收入贡献最大，创收--，占总收入的--%。
